Intra-Cellular Therapies, Inc. provides sales guidance for the fiscal year 2023. Full year 2023 CAPLYTA net product sales guidance increased to $460 to $470 million from the previous range of $445 to $465 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
67 USD | -5.91% | -7.88% | -6.45% |
May. 07 | Sector Update: Health Care Stocks Steady Pre-Bell Tuesday | MT |
May. 07 | Transcript : Intra-Cellular Therapies, Inc., Q1 2024 Earnings Call, May 07, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.45% | 7.07B | |
-3.35% | 88.91B | |
+4.08% | 41.25B | |
-15.09% | 31.99B | |
+52.22% | 24.73B | |
-15.13% | 15.54B | |
-8.63% | 12.05B | |
-40.39% | 12.07B | |
+6.22% | 8.84B | |
-5.15% | 8.3B |
- Stock Market
- Equities
- ITCI Stock
- News Intra-Cellular Therapies, Inc.
- Intra-Cellular Therapies, Inc. Provides Sales Guidance for the Fiscal Year 2023